BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 22867787)

  • 1. Bendamustine versus chlorambucil for the first-line treatment of chronic lymphocytic leukemia in England and Wales: a cost-utility analysis.
    Woods B; Hawkins N; Dunlop W; O'Toole A; Bramham-Jones S
    Value Health; 2012; 15(5):759-70. PubMed ID: 22867787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukaemia: updated results of a randomized phase III trial.
    Knauf WU; Lissitchkov T; Aldaoud A; Liberati AM; Loscertales J; Herbrecht R; Juliusson G; Postner G; Gercheva L; Goranov S; Becker M; Fricke HJ; Huguet F; Del Giudice I; Klein P; Merkle K; Montillo M
    Br J Haematol; 2012 Oct; 159(1):67-77. PubMed ID: 22861163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-Effectiveness Model for Chemoimmunotherapy Options in Patients with Previously Untreated Chronic Lymphocytic Leukemia Unsuitable for Full-Dose Fludarabine-Based Therapy.
    Becker U; Briggs AH; Moreno SG; Ray JA; Ngo P; Samanta K
    Value Health; 2016 Jun; 19(4):374-82. PubMed ID: 27325329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of First-line Chronic Lymphocytic Leukemia Treatments When Full-dose Fludarabine Is Unsuitable.
    Soini E; Hautala A; Poikonen E; Becker U; Kyttälä M; Martikainen J
    Clin Ther; 2016 Apr; 38(4):889-904.e14. PubMed ID: 26970696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bendamustine-rituximab: a cost-utility analysis in first-line treatment of indolent non-Hodgkin's lymphoma in England and Wales.
    Dewilde S; Woods B; Castaigne JG; Parker C; Dunlop W
    J Med Econ; 2014 Feb; 17(2):111-24. PubMed ID: 24308372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia.
    Knauf WU; Lissichkov T; Aldaoud A; Liberati A; Loscertales J; Herbrecht R; Juliusson G; Postner G; Gercheva L; Goranov S; Becker M; Fricke HJ; Huguet F; Del Giudice I; Klein P; Tremmel L; Merkle K; Montillo M
    J Clin Oncol; 2009 Sep; 27(26):4378-84. PubMed ID: 19652068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fludarabine phosphate for the first-line treatment of chronic lymphocytic leukaemia.
    Walker S; Palmer S; Erhorn S; Brent S; Dyker A; Ferrie L; Horsley W; Macfarlane K; White S; Thomas S
    Health Technol Assess; 2009 Jun; 13 Suppl 1():35-40. PubMed ID: 19567212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost Effectiveness of Ofatumumab Plus Chlorambucil in First-Line Chronic Lymphocytic Leukaemia in Canada.
    Herring W; Pearson I; Purser M; Nakhaipour HR; Haiderali A; Wolowacz S; Jayasundara K
    Pharmacoeconomics; 2016 Jan; 34(1):77-90. PubMed ID: 26518293
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The clinical effectiveness and cost-effectiveness of rituximab for the first-line treatment of chronic lymphocytic leukaemia: an evidence review of the submission from Roche.
    Main C; Pitt M; Moxham T; Stein K
    Health Technol Assess; 2010 Oct; 14(Suppl. 2):27-32. PubMed ID: 21047488
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bendamustine: inadequate or outdated data.
    Prescrire Int; 2012 Mar; 21(125):64. PubMed ID: 22428184
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab for the treatment of relapsed/refractory chronic lymphocytic leukaemia.
    Dretzke J; Barton P; Kaambwa B; Connock M; Uthman O; Bayliss S; Meads C
    Health Technol Assess; 2010 Oct; 14(Suppl. 2):19-26. PubMed ID: 21047487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bendamustine for the treatment of chronic lymphocytic leukemia and rituximab-refractory, indolent B-cell non-Hodgkin lymphoma.
    Dennie TW; Kolesar JM
    Clin Ther; 2009; 31 Pt 2():2290-311. PubMed ID: 20110042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bendamustine compared to fludarabine as second-line treatment in chronic lymphocytic leukemia.
    Niederle N; Megdenberg D; Balleisen L; Heit W; Knauf W; Weiß J; Freier W; Hinke A; Ibach S; Eimermacher H
    Ann Hematol; 2013 May; 92(5):653-60. PubMed ID: 23340738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-Effectiveness Analysis of Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukaemia in Portuguese Patients who are Unsuitable for Full-Dose Fludarabine-Based Therapy.
    Paquete AT; Miguel LS; Becker U; Pereira C; Pinto CG
    Appl Health Econ Health Policy; 2017 Aug; 15(4):501-512. PubMed ID: 28342061
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-Effectiveness of Ibrutinib Compared With Obinutuzumab With Chlorambucil in Untreated Chronic Lymphocytic Leukemia Patients With Comorbidities in the United Kingdom.
    Sinha R; Redekop WK
    Clin Lymphoma Myeloma Leuk; 2018 Feb; 18(2):e131-e142. PubMed ID: 29398648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of adding rh-endostatin to first-line chemotherapy in patients with advanced non-small-cell lung cancer in China.
    Wu B; Chen H; Shen J; Ye M
    Clin Ther; 2011 Oct; 33(10):1446-55. PubMed ID: 21992806
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bendamustine in the treatment of chronic lymphocytic leukemia.
    Knauf W
    Expert Rev Anticancer Ther; 2009 Feb; 9(2):165-74. PubMed ID: 19192955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-utility analysis of imatinib mesylate for the treatment of chronic myelogenous leukemia in the chronic phase.
    Warren E; Ward S; Gordois A; Scuffham P
    Clin Ther; 2004 Nov; 26(11):1924-33. PubMed ID: 15639704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-utility analysis of venetoclax in combination with obinutuzumab as first-line treatment of chronic lymphocytic leukaemia in Spain.
    Moreno-Martínez E; De la Serna-Torroba J; Escudero-Vilaplana V; Hernández-Rivas JÁ; Sánchez-Cuervo M; Sánchez-Hernández R
    Farm Hosp; 2022 Apr; 46(3):121-132. PubMed ID: 36183205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic evaluation of sequential treatments for follicular non-hodgkin lymphoma.
    Soini EJ; Martikainen JA; Vihervaara V; Mustonen K; Nousiainen T
    Clin Ther; 2012 Apr; 34(4):915-925.e2. PubMed ID: 22459623
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.